Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-06-27
2006-06-27
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252100, C544S336000
Reexamination Certificate
active
07067506
ABSTRACT:
Aryl- and heteroaryl-substituted urea compounds useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. Methods of making the compounds, and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or cell division also are disclosed.
REFERENCES:
patent: 4609659 (1986-09-01), Hartman
patent: 5041653 (1991-08-01), Lee et al.
patent: 5215738 (1993-06-01), Lee et al.
patent: 6218109 (2001-04-01), Elledge et al.
patent: 2132771 (1995-04-01), None
patent: 1 054 004 (2000-11-01), None
patent: 1 096 014 (2001-05-01), None
patent: 1 143 920 (2001-11-01), None
patent: 1 199 306 (2002-04-01), None
patent: 1621447 (1996-02-01), None
patent: 1624949 (1996-02-01), None
patent: WO 93/07128 (1993-04-01), None
patent: WO 94/26715 (1994-11-01), None
patent: 9611930 (1996-04-01), None
patent: WO 99/00357 (1999-01-01), None
patent: 9911621 (1999-03-01), None
patent: 9929674 (1999-06-01), None
patent: 9932433 (1999-07-01), None
patent: WO 99/32436 (1999-07-01), None
patent: WO 99/32463 (1999-07-01), None
patent: WO 00/03005 (2000-01-01), None
patent: 2000018738 (2000-04-01), None
patent: WO 00/26203 (2000-05-01), None
patent: WO 00/56725 (2000-09-01), None
patent: WO 00/75120 (2000-12-01), None
patent: WO 01/57034 (2001-08-01), None
Chemical Abstract DN 130:209605, also cited as WO 9911621.
Chemical Abstract DN 131:44827, also cited as WO9929674).
Chemical Abstract DN 128:13243, also cited as Arch. der Pharm.(Weinheim Germany) 330/7,207-10(1997).
Chemical Abstract DN 127:277898, also cited as Magnetic Reson. in Chem. 35/9,653-55(1997).
Chemical Abstract DN124:75535,also cited as J. Med. Chem. 39/1,304-13(1996).
Chemical Abstract DN 123:143653, also cited as CA 2132771 dated 4/12995.
Chemical Abstract DN 112:216860, also cited as Acta Poloniae Pharm. 46/2,101-13(1989).
Chemical Abstract DN 91:117865,also cited as Acta Ploniae Pharm. 35/5,615-18(1978).
Chaplin et al, Chemical Abstract DN 114:77895, also cited as British J. of Cancer, 62/4,561-6(1990).
Chemical Abstract DN:4609659, also cited as U.S.P. 4609659.
Carter et alChemotherapy of cancer, second edition, pp. 362-365(1981).
PubMed ASbstract 12554671, also cited as EMBO J. 22/3,713-23(2003).
PubMed ASbstract 8384080, also cited as Cancer Res. 53/7,1599-601(1993).
Cecil Textbook if medicine, 2oth edition, vol. 1, pp. 1004-1010(1996).
Uckun et al,Current Cancer Drug Targets, 1,59-71(2001).
PubMed Abstract 14593735, also cited as Prog. Cell Cycle Res.,5,413-21(2003).
PubMed ASbstract 12576328, also cited as Blood, 101/11,4589-97(2003).
Sanchez et al, Science, vol. 277, 1497-1501(1997).
S.P. Dutta et al.,J. Carbohydrates Nucleosides Nucleotides, 7(4), 217-240 (1980).
US 1993/03539, Apr. 20, 1993.
Burgess Laurence Edward
Cook Adam Wade
Cowen Scott Douglas
Gaudino John Joseph
Keegan Kathleen S.
ICOS Corporation
Marshall & Gerstein & Borun LLP
Patel Sudhaker B.
Raymond Richard L.
LandOfFree
Compounds useful for inhibiting Chk1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds useful for inhibiting Chk1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds useful for inhibiting Chk1 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3669803